NCT02003534View on ClinicalTrials.gov

A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

376

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Glaucoma, Open-AngleOcular Hypertension
Interventions
DRUG

0.15% Brimonidine Tartrate

0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.

Trial Locations (1)

Unknown

Shanghai

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY